special-rna-suppresses
Credit: Cell Reports (2024). DOI: 10.1016/j.celrep.2023.113644

Breast cancer is the most common cancer in women. The development of breast cancer often originates from epithelial cells in the mammary gland—the very cells that specialize in milk production during and after pregnancy.

A team of researchers from Friedrich Schiller University Jena (Germany), the university in Shenzhen (China) and Jena University Hospital (Germany) has taken a closer look at this specialization process and deciphered a molecular mechanism that also appears to play an important role in cancer development.

It may be possible to develop new diagnostic procedures and treatment methods for breast cancer based on these research findings now published in Cell Reports.

Cell differentiation, i.e., cell specialization, is the process by which cells take on different tasks. During lactogenesis—the process triggered by hormones that enables the mammary glands to produce milk—the relevant cells multiply first. The proteins required for this are produced by the ribosomes. A fundamental building block of ribosomes is ribosomal RNA, or rRNA for short.

If more proteins are required, the demand for rRNA also increases, and its synthesis in the cell nucleus is ramped up accordingly. At the end of lactogenesis, the specialized cells stop growing and reduce rRNA synthesis again. This regulatory mechanism takes place at the epigenetic level, which means that it is not the DNA itself that changes, but its packaging, for which another type of RNA is responsible.

“We’ve found out that a long, non-coding RNA called PAPAS, which I had discovered a few years ago, acts on the packaging of the DNA and reduces rRNA production,” explains Dr. Holger Bierhoff, who is leading the project at the University of Jena.

“More precisely, PAPAS influences access to the active regions of the DNA and determines whether these are copied into RNA or not. If a lot of ribosomes and proteins, and thus a lot of rRNA are needed, the synthesis of PAPAS is reduced. If this process is to be stopped, the PAPAS level is increased.”

The experts in Jena also discovered that PAPAS not only plays an important role in cell proliferation, but also in specialization. “When we switched off PAPAS through gene manipulation in cells, we observed that the development into milk-producing cells no longer functioned properly,” says Bierhoff.

 

High PAPAS level, low tumor growth

Synthesis of rRNA is also increased in cancer cells, as they multiply rapidly and require a lot of proteins—and accordingly a lot of ribosomes. “We therefore asked ourselves whether the regulatory mechanism we observed also plays a role in the development of breast cancer. The answer is clearly yes,” explains cell biologist Bierhoff.

“When we reduced PAPAS synthesis and switched off cell specialization, we observed that the cells developed the characteristics of cancer cells.” In contrast, the researchers showed both in cell cultures and in mice that a high PAPAS level reduces tumor growth as well as the spread of metastases.

But how do cancer cells manage to switch off PAPAS production and thus boost rRNA synthesis? “We have also found a mechanism for this,” explains Bierhoff. “Production of PAPAS requires a molecular signal at the start of the PAPAS gene. This signaling structure is regulated by particular proteins, which can resolve or block the structure. We’ve observed that the production of these proteins is particularly high in breast cancer cells. The more aggressive the tumor, the more of them are present.”

For Holger Bierhoff, the research results are promising in two respects. “First, we see that PAPAS can be an interesting marker for assessing the aggressiveness of a breast tumor. This information could potentially be used as a diagnostic tool,” he says. “Second, we’re already working on developing an RNA therapy for cancer treatment. We know the mechanism by which PAPAS regulates rRNA synthesis and we know which region of the RNA is required for this.

“Now, the idea is to produce this part of PAPAS artificially, package it in nanoparticles, and introduce it into the cancer cells, thereby restoring its function. In this way, we would reduce rRNA synthesis, which the cancer needs to proliferate.” This strategy would be similar to mRNA vaccines, like the one against COVID-19, however, here a regulatory RNA instead of protein-coding RNA would be applied.

Source:
https://medicalxpress.com/news/2024-01-special-rna-shown-suppress-formation.html
GMP mRNA
Check out our mRNA service to expedite your vaccine research
About PackGene

PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.

Related News

How to make mRNA therapeutics safe from the start

The success of mRNA vaccines against COVID-19 has unleashed a flood of interest in using the technology to create more vaccines and treatments for everything from rare diseases and infections to cancer. But before new mRNA therapeutics are put to use, they need to be...

read more

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE